Literature DB >> 16814357

In vitro replication capacity of HIV-2 variants from long-term aviremic individuals.

Hetty Blaak1, Marchina E van der Ende, Patrick H M Boers, Hanneke Schuitemaker, Albert D M E Osterhaus.   

Abstract

To establish whether efficient suppression of virus replication in HIV-2-infected individuals is associated with low replicative capacity of HIV-2, replication kinetics of HIV-2 variants from long-term aviremic individuals was analyzed and compared with that of the relatively slow-replicating HIV-1 variants from asymptomatics and long-term nonprogressors (AS/LTNP). On average, HIV-2 from aviremic individuals had lower replication rates than HIV-1 variants from AS/LTNP in cells of 8 donors (0.45 log10 [range 0.14-0.77] vs. 0.58 log10 [range 0.32-0.99] pg RT/ml/day, P = 0.036). The relatively low replication rate of HIV-2 compared to HIV-1 variants was not related to different sensitivities to inhibition by CD8+ T cells or different degrees of infectivity. HIV-2 replication rates increased with progressive infection and with switch from CCR5 to CXCR4 usage. The relatively low replicative capacity of HIV-2 variants from aviremic individuals likely contributes to the low viral load and benign course of infection in these individuals.

Entities:  

Mesh:

Year:  2006        PMID: 16814357     DOI: 10.1016/j.virol.2006.05.029

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated.

Authors:  Suzanne D G Kijewski; Hisashi Akiyama; Amin Feizpour; Caitlin M Miller; Nora-Guadalupe P Ramirez; Björn M Reinhard; Suryaram Gummuluru
Journal:  Virology       Date:  2016-08-11       Impact factor: 3.616

2.  Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.

Authors:  Melody G Duvall; Karin Loré; Hetty Blaak; David A Ambrozak; William C Adams; Kathlyn Santos; Christof Geldmacher; John R Mascola; Andrew J McMichael; Assan Jaye; Hilton C Whittle; Sarah L Rowland-Jones; Richard A Koup
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

3.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.

Authors:  Julia Drylewicz; Sophie Matheron; Estibaliz Lazaro; Florence Damond; Fabrice Bonnet; François Simon; François Dabis; Françoise Brun-Vezinet; Geneviève Chêne; Rodolphe Thiébaut
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

Review 4.  Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.

Authors:  M T Boswell; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

5.  Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

Authors:  Thushan I de Silva; Marlén Aasa-Chapman; Matthew Cotten; Stéphane Hué; James Robinson; Frederic Bibollet-Ruche; Ramu Sarge-Njie; Neil Berry; Assan Jaye; Peter Aaby; Hilton Whittle; Sarah Rowland-Jones; Robin Weiss
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

6.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

7.  Different effects of the TAR structure on HIV-1 and HIV-2 genomic RNA translation.

Authors:  Ricardo Soto-Rifo; Taran Limousin; Paulina S Rubilar; Emiliano P Ricci; Didier Décimo; Olivier Moncorgé; Mary-Anne Trabaud; Patrice André; Andrea Cimarelli; Théophile Ohlmann
Journal:  Nucleic Acids Res       Date:  2011-11-24       Impact factor: 16.971

8.  Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting.

Authors:  Jamil S Saad; Sherimay D Ablan; Ruba H Ghanam; Andrew Kim; Kalola Andrews; Kunio Nagashima; Ferri Soheilian; Eric O Freed; Michael F Summers
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

9.  The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals.

Authors:  Hangxing Yu; Shariq M Usmani; Alexandra Borch; Julia Krämer; Christina M Stürzel; Mohammad Khalid; Xuehua Li; Daniela Krnavek; Marchina E van der Ende; Albert D Osterhaus; Rob A Gruters; Frank Kirchhoff
Journal:  Retrovirology       Date:  2013-03-05       Impact factor: 4.602

10.  The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.

Authors:  Pedro Borrego; José Maria Marcelino; Cheila Rocha; Manuela Doroana; Francisco Antunes; Fernando Maltez; Perpétua Gomes; Carlos Novo; Helena Barroso; Nuno Taveira
Journal:  Retrovirology       Date:  2008-09-08       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.